173 related articles for article (PubMed ID: 28032275)
21. MYC and BCL-2 adjusted-International Prognostic Index (A-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.
Wang J; Zhou M; Xu JY; Yang YG; Zhang QG; Zhou RF; Chen B; Ouyang J; Li C
Histol Histopathol; 2016 Mar; 31(3):285-92. PubMed ID: 26424560
[TBL] [Abstract][Full Text] [Related]
22. CD109: a multifunctional GPI-anchored protein with key roles in tumor progression and physiological homeostasis.
Mii S; Enomoto A; Shiraki Y; Taki T; Murakumo Y; Takahashi M
Pathol Int; 2019 May; 69(5):249-259. PubMed ID: 31219232
[TBL] [Abstract][Full Text] [Related]
23. CD109 and squamous cell carcinoma.
Qi R; Dong F; Liu Q; Murakumo Y; Liu J
J Transl Med; 2018 Apr; 16(1):88. PubMed ID: 29625613
[TBL] [Abstract][Full Text] [Related]
24. Epidermal hyperplasia and appendage abnormalities in mice lacking CD109.
Mii S; Murakumo Y; Asai N; Jijiwa M; Hagiwara S; Kato T; Asai M; Enomoto A; Ushida K; Sobue S; Ichihara M; Takahashi M
Am J Pathol; 2012 Oct; 181(4):1180-9. PubMed ID: 22846721
[TBL] [Abstract][Full Text] [Related]
25. Up-regulation of CD109 expression is associated with carcinogenesis of the squamous epithelium of the oral cavity.
Hagiwara S; Murakumo Y; Sato T; Shigetomi T; Mitsudo K; Tohnai I; Ueda M; Takahashi M
Cancer Sci; 2008 Oct; 99(10):1916-23. PubMed ID: 19016750
[TBL] [Abstract][Full Text] [Related]
26. CD109 identified in circulating proteomics mitigates postoperative recurrence in chronic rhinosinusitis with nasal polyps by suppressing TGF-β1-induced epithelial-mesenchymal transition.
Gao R; Chen Y; Liu H; Ye M; Chu L; Wang T
Int Immunopharmacol; 2024 Mar; 130():111793. PubMed ID: 38442581
[TBL] [Abstract][Full Text] [Related]
27. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
Troppan KT; Melchardt T; Deutsch A; Schlick K; Stojakovic T; Bullock MD; Reitz D; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Egle A; Pichler M
Eur J Haematol; 2015 Dec; 95(6):538-44. PubMed ID: 25677782
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
[TBL] [Abstract][Full Text] [Related]
29. MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway.
Wang WG; Jiang XN; Liu ZB; Zhou XY; Li XQ
Am J Surg Pathol; 2017 Apr; 41(4):541-549. PubMed ID: 28291124
[TBL] [Abstract][Full Text] [Related]
30. Transgenic mice overexpressing CD109 in the epidermis display decreased inflammation and granulation tissue and improved collagen architecture during wound healing.
Vorstenbosch J; Gallant-Behm C; Trzeciak A; Roy S; Mustoe T; Philip A
Wound Repair Regen; 2013; 21(2):235-46. PubMed ID: 23438099
[TBL] [Abstract][Full Text] [Related]
31. CD43 expression in diffuse large B-cell lymphoma, not otherwise specified: CD43 is a marker of adverse prognosis.
Ma XB; Zheng Y; Yuan HP; Jiang J; Wang YP
Hum Pathol; 2015 Apr; 46(4):593-9. PubMed ID: 25682152
[TBL] [Abstract][Full Text] [Related]
32. [The clinical characteristics of 681 patients with diffuse large B-cell lymphoma].
Wen JJ; Liu ZB; Xu J; Xu CG
Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1004-9. PubMed ID: 23363791
[TBL] [Abstract][Full Text] [Related]
33. TNF-α expression in tumor cells as a novel prognostic marker for diffuse large B-cell lymphoma, not otherwise specified.
Nakayama S; Yokote T; Hirata Y; Akioka T; Miyoshi T; Hiraoka N; Iwaki K; Takayama A; Nishiwaki U; Masuda Y; Nishimura Y; Tsuji M; Hanafusa T
Am J Surg Pathol; 2014 Feb; 38(2):228-34. PubMed ID: 24145654
[TBL] [Abstract][Full Text] [Related]
34. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
[TBL] [Abstract][Full Text] [Related]
35. Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wong KK; Ch'ng ES; Loo SK; Husin A; Muruzabal MA; Møller MB; Pedersen LM; Pomposo MP; Gaafar A; Banham AH; Green TM; Lawrie CH
Exp Mol Pathol; 2015 Dec; 99(3):537-45. PubMed ID: 26341140
[TBL] [Abstract][Full Text] [Related]
36. CD109 expression in tumor cells and stroma correlates with progression and prognosis in pancreatic cancer.
Adachi K; Sakurai Y; Ichinoe M; Tadehara M; Tamaki A; Kesen Y; Kato T; Mii S; Enomoto A; Takahashi M; Koizumi W; Murakumo Y
Virchows Arch; 2022 Apr; 480(4):819-829. PubMed ID: 34762199
[TBL] [Abstract][Full Text] [Related]
37. CD109 is identified as a potential nasopharyngeal carcinoma biomarker using aptamer selected by cell-SELEX.
Jia W; Ren C; Wang L; Zhu B; Jia W; Gao M; Zeng F; Zeng L; Xia X; Zhang X; Fu T; Li S; Du C; Jiang X; Chen Y; Tan W; Zhao Z; Liu W
Oncotarget; 2016 Aug; 7(34):55328-55342. PubMed ID: 27419372
[TBL] [Abstract][Full Text] [Related]
38. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
39. [Influence of transplantation and some clinical factors on prognosis of patients with diffuse large B-cell lymphoma].
Zhao SX; Han Y; Zhu Q; Wang Q; Zhang WJ; Chen XC; Sun AN; Jin ZM; Qiu HY; Tang XW; Fu ZZ; He GS; Miao M; Ma X; Wu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):623-7. PubMed ID: 23815910
[TBL] [Abstract][Full Text] [Related]
40. LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy.
Peng W; Wu J; Feng J
Clin Exp Med; 2017 Feb; 17(1):1-8. PubMed ID: 26475621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
